Alnylam boots Type 2 diabetes asset from haunted house

Alnylam is suspending further development of a clinical-stage RNAi therapeutic designed to treat Type 2 diabetes among participants with obesity.

The discontinuation is part of portfolio prioritization efforts shared in an Oct. 31 third-quarter earnings release.